Brief: MaxCyte Announces Strategic Platform Licensing Agreement With Anocca AB To Advance Tcr-T Cell Therapy Pipeline
31/07/2025 14:41
July 31 (Reuters) - MaxCyte Inc MXCT.O: MAXCYTE ANNOUNCES STRATEGIC PLATFORM LICENSING AGREEMENT WITH ANOCCA AB TO ADVANCE TCR-T CELL THERAPY PIPELINE Source text: ID:nGNX1GsYrb Further company coverage: MXCT.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on MaxCyte
See all newsMaxCyte Q1 revenue falls
Brief: Maxcyte Appoints Parmeet Ahuja As Chief Financial Officer
Brief: Maxcyte Announces Preliminary Unaudited Fourth Quarter And Full Year 2025 Financial Results
MaxCyte Q3 revenue falls 16% hurt by lower sales in instruments
Brief: MaxCyte Announces Planned CFO Transition In 2026